9537 Background: Non-hormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind, placebo-controlled studies involving newer antidepressants and gabapentin have evaluated these non-hormonal agents for decreasing hot flashes from a no-treatment baseline period, inclusive of all known such published trials through 2007. Methods: Individual patient data were collected. Between-study heterogeneity was tested via chi- square tests prior to a pooled analyses. The change in hot flash activity from baseline to week 4 for each agent was calculated via both weighted and unweighted approaches using the size of the study as the weight. The effect size was recalculated using an unweighted approach to test the sensitivity of the results relative to the influence of individual study sample sizes. Regression models and linear random effects were used to adjust for age, breast cancer history, and tamoxifen usage on hot flash activity. Results: Data from 1,341 patients indicated that paroxetine (2 studies), venlafaxine (1 study), fluoxetine (1 study), and sertraline (3 studies) decreased absolute hot flash scores by 41%, 33%, 13%, and 3%-18% more than did their corresponding placebo arms, respectively. As a group, the antidepressants decreased absolute hot flash scores by 26 % more than was seen with their corresponding placebo arms (P= 0.0001). The three gabapentin trials decreased absolute hot flashes by 35–38% more than did their corresponding placebo arms (P= 0.0001). Results were similar for the weighted and unweighted effect size approaches. Age, breast cancer history, and tamoxifen usage did not impact the findings. Conclusions: Newer antidepressants, as a group, and gabapentin decrease hot flashes significantly more than do placebos. There may be efficacy differences among the different antidepressants. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Concert Pharmaceuticals, JDS Pharmaceuticals, Wyeth
Read full abstract